Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Gains from Sales and Divestitures: 2012-2014

Historic Gains from Sales and Divestitures for Madrigal Pharmaceuticals (MDGL) over the last 3 years, with Dec 2014 value amounting to $39,508.

  • Madrigal Pharmaceuticals' Gains from Sales and Divestitures rose 52.47% to $45,361 in Q3 2015 from the same period last year, while for Sep 2015 it was $45,361, marking a year-over-year increase of 52.47%. This contributed to the annual value of $39,508 for FY2014, which is 28.33% down from last year.
  • As of FY2014, Madrigal Pharmaceuticals' Gains from Sales and Divestitures stood at $39,508, which was down 28.33% from $55,122 recorded in FY2013.
  • In the past 5 years, Madrigal Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $92,571 in FY2012 and a low of $39,508 during FY2014.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Gains from Sales and Divestitures value was $55,122 (recorded in 2013), while the average stood at $62,400.
  • Data for Madrigal Pharmaceuticals' Gains from Sales and Divestitures shows a maximum YoY crashed of 40.45% (in 2013) over the last 5 years.
  • Yearly analysis of 3 years shows Madrigal Pharmaceuticals' Gains from Sales and Divestitures stood at $92,571 in 2012, then slumped by 40.45% to $55,122 in 2013, then declined by 28.33% to $39,508 in 2014.